Clinical trials: Hepatic Tumor Resection, active
Hepatocellular Carcinoma (HCC)
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii.
- Trial name
- NCT07075120
- Testing
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Hepato Cellular Carcinoma (HCC), Immunotherapy
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.
- Trial name
- NCT07461675
- Testing
- Atezolizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Geneva, Switzerland
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Liver Tumours, Liver Cancer (Primary and Metastatic)
Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy
The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy.
- Conditions
- Liver Tumours, Liver Cancer (Primary and Metastatic), Liver Resection, Liver Hypertrophy
- Trial name
- I-GROWtoh (NCT07445412)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Liver Cancer (Primary and Metastatic)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer.
- Trial name
- Archer (NCT07684040)
- Testing
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had…
- Trial name
- NCT07709299
- Testing
- Autologous Cytokine-Induced Killer (CIK) Cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Liver Resection, Liver Tumours
Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA).
Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA) Introduction The mode of parenchymal transection in hepatic resection has been a topic of great debate for decades.
- Conditions
- Liver Resection, Liver Tumours, Liver Transplant Disorder, Trauma Abdomen
- Trial name
- NCT07142876
- Testing
- Liver resection Cavitron Ultrasonic Surgical Aspirator (CUSA), Liver resection with the harmonic scalpel
- Volunteers
- 50 people
- Sponsor
- Sohag University
Colorectal Liver Metastasis (CRLM), Liver Resection
The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases
Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Survival is primarily determined by stage of disease and the presence of metastases.
- Conditions
- Colorectal Liver Metastasis (CRLM), Liver Resection, Hepatectomy, Liver Ablation
- Trial name
- AI-RECOLMET (NCT07385521)
- Testing
- AI-analysis
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Francesco De Cobelli
Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
This study will evaluate nivolumab and ipilimumab, two immunotherapy medicines, given before repeat liver surgery in adults whose liver cancer (hepatocellular carcinoma) has returned within the liver after previous surgery.
- Trial name
- CA209-1594 (NCT07919717)
- Testing
- Nivolumab, Ipilimumab, Repeat Hepatectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
Surgery, Liver Tumor
Evaluation of Resection Techniques for Pancreatic Tumors
The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.
- Conditions
- Surgery, Liver Tumor, Pancreas Tumor
- Trial name
- NCT05128890
- Testing
- Resection techniques for pancreatic and liver tumors
- Where
- United States
- Volunteers
- 431 people
- Sponsor
- Methodist Health System
Hepatocellular Carcinoma
Antiviral Therapy for Patients With Liver Cancer After Surgery
This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF)…
- Trial name
- NCT05466565
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatocellular Carcinoma (HCC)
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
Hepatocellular carcinoma, the most common type of primary liver cancer, can recur after liver resection or thermal ablation performed with curative intent.
- Trial name
- HCC-AI-RECLAIM (NCT07732504)
- Testing
- Artificial Intelligence-Guided Risk-Adapted Surveillance, Fixed-Interval Surveillance
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC)
NWRD06 DNA Plasmid for HCC After Curative Resection.
This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma…
- Trial name
- NCT07324304
- Testing
- NWRD06 administered by electroporation
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Hepatocellular Carcinoma (HCC), Liver Diseases
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene…
- Trial name
- NCT07150624
- Testing
- Experimental Group, control group
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Anhui Provincial Hospital
Liver Cancer, Adult, Metastases to Liver
15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial
The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors.
- Conditions
- Liver Cancer, Adult, Metastases to Liver, Liver Malignant Tumors
- Trial name
- NCT07237204
- Testing
- Pringle manouver
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Medical University of Warsaw
Hepatocellular Carcinoma
Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial
Hepatocellular carcinoma (HCC) is the most common primary liver tumor. Surgical resection remains the first choice for early-stage HCC because the result is superior to other treatments and not limited to liver donation.
- Trial name
- NCT06193733
- Testing
- Autologous Dendritic Cell
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC)
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative…
- Trial name
- NCT04639180
- Testing
- Camrelizumab, Rivoceranib (Apatinib)
- Where
- 6 sites in China
- Volunteers
- 687 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.